Elite Pharmaceuticals announced the US Food and Drug Administration’s acceptance for review of an Abbreviated New Drug Application on December 21, 2023, for an undisclosed generic drug product in a class of medications known as central nervous stimulants.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ELTP: